IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,164 shares of the medical research company's stock after purchasing an additional 3,872 shares during the quarter. Nomura Asset Management Co. Ltd.'s holdings in IQVIA were worth $12,835,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of IQV. Canada Pension Plan Investment Board lifted its stake in IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after acquiring an additional 211,653 shares during the period. Farallon Capital Management LLC lifted its position in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company's stock valued at $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC boosted its holdings in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. Impax Asset Management Group plc grew its position in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after purchasing an additional 157,809 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of IQVIA by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company's stock valued at $320,170,000 after buying an additional 11,715 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. BTIG Research dropped their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Morgan Stanley dropped their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Leerink Partners reiterated an "outperform" rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Robert W. Baird dropped their price target on shares of IQVIA from $213.00 to $212.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $257.60.

IQVIA Price Performance

IQV stock traded down $0.70 during mid-day trading on Thursday, reaching $200.37. The company's stock had a trading volume of 1,156,252 shares, compared to its average volume of 1,186,217. The stock has a market cap of $36.37 billion, a PE ratio of 26.29, a P/E/G ratio of 2.08 and a beta of 1.49. The company's 50 day moving average is $213.40 and its two-hundred day moving average is $224.61. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.